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In vitro photosensitization of tumour cell enzymes by Photofrin II
administered in vivo
S.L. Gibson, R.S. Murant, M.D. Chazen, M.E. Kelly & R. Hilf
Department of Biochemistry and University of Rochester Cancer Center, University of Rochester School of Medicine and
Dentistry, Rochester, NY, USA.
Summary The ability of injected Photofrin II, a preparation enriched in hydrophobic dihaematoporphyrin
ethers and esters, to photosensitize selected mitochondrial and cytosolic enzymes during illumination in vitro
was examined. Preparations of R3230AC mammary tumours, obtained at designated times after a single dose
of Photofrin II, displayed a time-dependent photosensitivity. Maximum inhibition of mitochondrial enzymes
occurred at 24 hours post-treatment, whereas no inhibition of the cytosolic enzyme, pyruvate kinase, was
observed over the 168 hour time course. At the selected 24 hour time point, mitochondrial enzyme
photosensitisation was found to be drug dose (5-25mgkg-1 Photofrin II) and light dose dependent, the rank
order of inhibition being cytochrome c oxidase >FOF ATPase >succinate dehydrogenase >NADH
dehydrogenase. We conclude that porphyrin species contained in Photofrin II accumulate in mitochondria of
tumour cells in vivo and produce maximum photosensitisation at 24-72 hours after administration to tumour-
bearing animals. The time course observed here with Photofrin II is similar to that seen previously with the
more heterogenous haematoporphyrin derivative preparation in this in vivo-in vitro model.
Photodynamic therapy (PDT), a recently developed
treatment for management of malignancies, is initiated by
systemic administration of a photosensitising agent, either
haematoporphyrin derivative (HpD) or the commercially
available semi-purified preparation called Photofrin II, which
is preferentially retained in tumour tissue (Lipson et al.,
1960; Gomer & Dougherty, 1979). After 24-72h, to allow
clearance of the photosensitiser from normal tissues, the
malignant lesions are exposed to visible light, usually by
laser irradiation. Tumour necrosis and regression ensue from
photoradiation. It is generally agreed that cytotoxicity is
mediated via formation of the highly reactive oxygen species,
singlet oxygen, 102, (Weishaupt et al., 1976; Gibson et al.,
1984; Parker, 1987). Since the original promising clinical
results utilised HpD, a crude preparation composed of at
least seven different porphyrin species (Gibson et al., 1984;
Kessel, 1986; Moan et al., 1987), subsequent investigations
were directed towards determination of the chemical
structure of the 'active component' of HpD (Moan et al.,
1982; Kessel and Chou, 1983; Dougherty et al., 1984).
Methods developed to purify HpD produced a porphyrin
mixture enriched in the hydrophobic components, reported
to be mainly dihaematoporphyrin ethers or esters (Byrne et
al., 1987; Dougherty, 1987; Kessel et al., 1987). This
enriched preparation, Photofrin II, is now commercially
produced for clinical and laboratory studies.
In our earlier studies we utilised HpD as the photo-
sensitiser (Hilf et al., 1983, 1984; Gibson & Hilf, 1983;
Gibson et al., 1984). Because of the complex nature of HpD,
the intracellular localisation and effects of various photo-
sensitising components relative to time after administration
could differ from the pharmacokinetics that would be
observed with Photofrin II. We therefore undertook a study
of Photofrin II employing the same in vivo-in vitro protocol
used previously for HpD (Hilf et al., 1984). In this protocol,
the photosensitiser is injected into tumour-bearing animals,
tumours are removed and subcellular organelles are
prepared. These preparations are then exposed to visible
light in vitro, and various biochemical endpoints are
analysed, such as site-specific enzyme activities. One
advantage of this protocol is that it takes into account any
metabolism of the sensitiser by the tumour-bearing host. In
this report, using Photofrin II as the photosensitiser, data
are presented on the time-course and drug dose response of
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photosensitisation of selected mitochondrial and cytosolic
enzymes in the R3230AC mammary carcinoma.
Materials and methods
Materials
Photofrin II was kindly provided by Photomedica Inc.,
Raritan, NJ. All other reagents were obtained from Sigma
Chemical Co., St Louis, MO, unless otherwise noted.
Animals and tumours
The R3230AC mammary adenocarcinoma was maintained
by subcutaneous transplantation in the axillary region of 60-
80g female Fischer rats, using the sterile trochar procedure
described previously (Hilf et al., 1965).
Preparation of subcellular organelles from tumours
For in vitro studies, tumour-bearing rats were killed 17-24
days after implantation of the R3230AC mammary adeno-
carcinoma. From excised tumours, mitochondria were
prepared according to methods described earlier (Gibson &
Hilf, 1983). Briefly, R3230AC tumours were removed,
weighed, placed in a dish on ice in 0.9% NaCl solution and
minced with scissors. Approximately 2g of minced tumour
tissue was transferred to 5ml of ice cold buffer, pH7.4,
containing 0.33 M sucrose, I mM dithiothreitol, 1 mM
ethyleneglycol bis (fl-aminoethyl)-N,N'-tetraacetic acid
(EGTA), 0.03% bovine serum albumin and 100mM KCI.
Tissues were homogenised on ice, with two 15-second bursts,
with a Polytron homogeniser (Brinkmann Industries,
Westbury, NY) at a setting of six. The homogenate was
centrifuged at 500g for 30min at 4°C, the supernatant was
removed and centrifuged at 15,000g for 30 min at 4°C. The
resulting pellet was resuspended in 4ml ice cold
homogenising buffer (see above) and centrifuged at 15,000g
for 30 min at 4°C. This final pellet was resuspended in
homogenisation buffer (1.5ml), which typically yielded 10-
20mg mitochondrial protein per ml buffer. This mito-
chondrial suspension was apportioned in 0.5ml aliquots and
frozen at -70°C until used. All procedures were performed
in dim room light.
Treatment of mitochondrial suspensions with Photofrin II
in vitro
Stock solutions of Photofrin II were received frozen, thawed
at room temperature, divided into 1 ml aliquots and stored
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at -70°C until used. All experiments were performed using
dilutions of this stock preparation. Final concentrations of
PIT (0.7, 3.5, 7.0 and 35pgml-1) were added directly to the
mitochondrial suspensions prepared from tumours of
untreated rats and allowed to incubate in the dark at room
temperature for 10min. The suspensions were then
centrifuged at 8,000g, the supernatant containing the
unbound porphyrin was removed and the mitochondria were
resuspended in preparation buffer (Gibson & Hilf, 1983)
before photoradiation.
Administration of Photofrin II to tumour-bearing hosts; in
vivo-in vitro protocol
The same in vivo-in vitro protocol employed earlier (Hilf et
al., 1984) was used to study the time course and dose
relationships of Photofrin II. For the time course, tumour-
bearing rats were injected i.p. with 25mgkg-1 Photofrin IT
and killed at various selected times after drug administration
(30min, 2, 6, 18, 24, 48, 72, 120 or 168h). Mitochondria
were prepared from excised tumour tissues, the remaining
portions of tumours were frozen and stored at -70°C until
used for preparation of cytosols as described previously (Hilf
et al., 1984). Determination of the drug dose related effects
was accomplished by injection i.p. of various doses of
Photofrin II (2.5, 5.0, 10.0 and 25.Omgkg-1). In these dose
studies, all animals were killed at 24h after Photofrin II
administration, tumours were removed and the procedures
described above were used for the preparation of mito-
chondria and cytosols.
Photoradiation conditions
Photoradiation of mitochondrial suspensions or of cytosol
preparations was conducted in 3ml glass cuvettes by
exposing a ml volume of either preparation to a cm
diameter focused and filtered (570-700nm) beam emitted
from a quartz-halogen light source. The samples were
continuously stirred magnetically, the temperature was
monitored and found not to rise above ambient 22°C. The
power dose for all experiments was maintained at
150mWcm-2 as measured with an RK5200 power
radiometer connected to an RK545 radiometer probe (Laser
Precision Inc., Utica, NY). At selected times, aliquots (10-
40 p1) were removed and assayed for enzyme activity.
Included in each experiment were controls: suspensions of
mitochondria or cytosol preparations exposed to
Photofrin II but not photoradiated (dark controls), and
preparations not exposed to Photofrin II that were
photoradiated (light controls). Enzyme activities in these
controls did not vary ±10% from initial values.
Enzyme activity analysis
The activities of cytochrome c oxidase and succinate de-
hydrogenase (SDH) were analysed as previously (Gibson &
Hilf, 1983; Hilf et al., 1984). Control activities (before
photoradiation) ranged from 0.4 to 0.6,pmol cytochrome c
oxidised per min per mg protein for cytochrome c oxidase
and from 4.6 to 8.3 x 10-2pmol INT oxidised per min per
mg protein for SDH.
NADH dehydrogenase activity was measured by the
method of King & Howard (1962): 30yl of mitochondrial
suspension were used and enzyme activity was assayed by
monitoring, in a spectrophotometer at 420nm, the reduction
of ferricyanide. Enzyme activity was converted to equivalents
of NADH oxidised per min; control values (before
irradiation) ranged from 1.75 to 2.62,pmol NADH oxidised
per min per mg protein.
The catalytic activity of FOFI ATP synthase was analysed
in sonicated mitochondrial suspensions (five 30s periods of
sonication on ice using a Biosonic III probe sonicator,
adjusted to a setting of 35; Bronwill Scientific, Rochester,
NY). Briefly, 30pl of the sonicated mitochondrial suspension
(approximately 200 pg protein per ml) was added to 1 ml of
reaction mixture containing 50mMTris, pH8.5, 10mMATP
and 4mM MgCl2 to obtain the total ATPase activity;
concurrently, a separate 30,pl of sonicated mitochondrial
suspension was added to the above reaction mixture
containing, in addition, 25pgml i- of oligomycin to
determine the oligomycin-sensitive ATPase activity. The
difference between total and oligomycin-sensitive activity
provides a measure of the catalytic activity of the FoFl ATP
synthase (in intact, non-sonicated, mitochondria the enzyme
would utilise ADP and Pi to form ATP whereas, in the assay
used here, it catalyses the reverse reaction, ATP -.ADP + Pi).
The reactions were incubated for 45min at 37°C in a shaking
water bath (New Brunswick Scientific, New Brunswick, NJ),
tubes containing the samples were removed and I ml of 10%
sodium dodecyl sulphate (SDS) was added to terminate the
reactions. The amount of Pi released was analysed (Taussky
& Shorr, 1953). The activity of the FOFI ATPase ranged
from 2.3 x 10-2 to 4.3 x 10-2pumol Pi released per min per
mg protein (mean 3.0 x 10-2).
Pyruvate kinase, an enzyme located in the cytosol, was
assayed using 20p1 aliquots of cytosols prepared from 10%
tumour homogenates, according to methods described earlier
(Hilf et al., 1965). Control activities (analysis before
photoradiation) were 0.742+0.096 pmol NADH oxidised per
min per mg protein. All incubations required to determine
enzyme activity were performed in the dark.
Data analysis
Data obtained for the effects of porphyrin photosensitisation
are expressed as percentage of initial activity (zero time), the
activity determined on samples before exposure to photo-
radiation. Rates of inhibition of enzyme activity were
calculated from regression analysis of the linear portion of
the inhibition curves. Results are presented as the mean
+s.e.m.
Results
Photosensitisation of mitochondrial NADH dehydrogenase by
Photofrin II in vitro
Before undertaking the in vivo-in vitro protocol study, we
investigated whether Photofrin II could photosensitise mito-
chondrial NADH dehydrogenase in vitro. This enzyme is
located in the inner membrane of mitochondria and
functions to catalyse the reduction of ferricyanide,
menadione, cytochrome c and coenzyme Q, constituents of
Complex I of the respiratory chain. The data obtained in
these experiments are illustrated in Figure 1. Photofrin II-
induced photosensitisation of mitochondrial suspensions was
manifested as a dose- and fluence-dependent inhibition of
NADH dehydrogenase activity in vitro. The inset in Figure 1
depicts the rate of inhibition of NADH dehydrogenase at
each concentration of Photofrin II used (0.7, 3.5, 7.0 and
35.0pg/ml). The data depict a reasonably linear relationship
between inhibition of NADH dehydrogenase activity and the
Photofrin II concentration used up to 7.0pgml- 1; above this
dose, however, linearity was lost. Thus, the activity of
NADH dehydrogenase in isolated mitochondria could be
inhibited by 50-60% by the higher concentrations of
Photofrin II plus light in vitro.
Effects of Photofrin II administered in vivo on photo-
sensitisation of enzyme activity in vitro
After administration of 25mgkg-1 Photofrin II to tumour-
bearing rats, tumours were obtained at selected times for
study of the effects of photoradiation in vitro on enzymes in
mitochondria and cytosols. Results of the time-course of
these responses in samples obtained from 30min to 168 h
after drug administration are illustrated in Figure 2. The
pattern of responses appears to fall into three categories,
based on the extent of inhibition observed. Pyruvate kinase,
which is localised in the cytosol, displayed little or no
inhibition of activity over the entire time course. NADH-PHOTOFRIN II AND TUMOUR ENZYMES 49
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Figure 1 Photofrin II concentration and fluence relationships
for the inhibition of the activity of mitochondrial NADH de-
hydrogenase in vitro. Mitochondria, prepared from tumours of
untreated rats as described in Materials and methods, were
exposed to various concentrations of Photofrin II;
0.7pgml- 1(), 3.5Mgml-
' (0), 7.Opgml- '(O) and
35/igml-'(0). NADH dehydrogenase activity was analysed at
various times during photoradiation (conditions detailed in
Materials and methods). Data are presented as percentage of
initial enzyme activity (zero time before light exposure). Each
data point represents the mean of at least six separate
experiments performed in duplicate. Error bars are the s.e.m. The
inset represents the calculated rates of enzyme inhibition
(% inhibition per Jcm-2) in relation to the Photofrin II
concentration.
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dehydrogenase activity, which was inhibited maximally to
35% at 24h after Photofrin II administration, displayed
inhibition of activity approximating 20% of control activity
up to the 96h time point. The other inner membrane
mitochondrial enzymes, cytochrome c oxidase, succinate
dehydrogenase and FoFl ATPase, displayed the greatest
inhibition of activity and all showed a similar pattern over
the time course studied. Maximum inhibition of activity was
observed when mitochondria were irradiated at 24-72h after
injection of Photofrin II. However, even at the latest time
point examined, 168h, photo-induced inhibition of enzyme
activity (40-50%) was still demonstrable. These results
demonstrate that certain mitochondrial enzymes located in
the inner mitochondrial membrane are highly susceptible to
photosensitisation by Photofrin II in this in vivo-in vitro
protocol, whereas pyruvate kinase, an enzyme located in the
cytosol, was virtually unaffected throughout the time course
studied.
Relationship of administered dose of Photofrin II on photo-
induced inhibition of mitochondrial enzymes
We next investigated whether the observed photosensitisation
of mitochondrial enzymes was directly related to the
administered dose of Photofrin II. The 24h time point
subsequent to administration of Photofrin II was selected,
since this appeared to be the earliest time when maximal
enzyme inhibition was obtained. The Photofrin II doses
employed were 2.5, 5.0, 10.0 and 25mgkg-1; the results are
depicted in Figure 3. The data demonstrate that each of the
four mitochondrial enzymes studied displayed a dose- and
fluence-dependent inhibition of activity. From these data, a
rate of enzyme inhibition was calculated (% inhibition per
Jcm-2) for each dose of Photofrin II administered in vivo.
The rates were obtained by regression analysis of the initial
region of the inhibition curve up to 270Jcm 2 total fluence.
When % inhibition per Jcm-2 was plotted against drug dose
(mgkg-1), a linear relationship was generally obtained, with
deviation from linearity occurring only at the highest drug
96 168
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Figure 2 Time course of photosensitisation of enzymes -in preparations of R3230AC mammary tumours following in vivo
administration of 25mgkg-1 Photofrin II. Preparation of mitochondria and cytosols are detailed in Materials and methods.
Enzyme activities analysed were pyruvate kinase (A), NADH dehydrogenase (U), succinate dehydrogenase (O), cytochrome c
oxidase (A) and FoF, ATPase (C1). Each data point represents the mean of at least four separate experiments (one tumour-bearing
animal per experiment), each assay performed in duplicate. Data are presented as percentage of initial (zero time) activity. Error
bars are the s.e.m.50 S.L. GIBSON et al.
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Figure 3 Relationship of Photofrin II dose in vivo and fluence on the inhibition of selected mitochondrial enzymes. Mitochondria
were prepared from tumours 24h after injection with various doses of Photofrin II; 2.5mgkg-1 (A), 5.0mgkg -(A),
10.0mg kg - (Ol) and 25 mg kg-' (U). Each panel depicts the results obtained for assay of each enzyme at each dose of
Photofrin II used; (a) cytochrome c oxidase; (b) FoF, ATPase; (c) succinate dehydrogenase; (d) NADH dehydrogenase. Data are
expressed as percentage of initial enzyme activity (zero time before photoradiation of mitochondria). Each data point represents the
mean of at least three separate experiments (one tumour-bearing animal per experiment). Error bars are the s.e.m. The inset in each
panel represents the calculated rate of enzyme inhibition in relation to the Photofrin II dose administered in vivo.
dose for SDH and NADH dehydrogenase (see insets in
Figure 3). These relationships between rate of inhibition and
drug dose exhibited correlation coefficients of r =0.97 or
greater. The slopes of these lines can provide an estimate of
relative sensitivity to photosensitisation for each enzyme.
The values, % inhibition per Jcm-2 x 10-2 per mg
administered dose of Photofrin II, are: cytochrome c oxidase,
0.98; FOFI ATPase, 0.77; succinate dehydrogenase, 0.49; and
NADH dehydrogenase, 0.26. These data indicate that there
are differences in the susceptibility of inner mitochondrial
enzymes to photosensitisation by Photofrin II. It is
interesting that over the time course studied, NADH
dehydrogenase was the least affected under the conditions
used in this in vivo-in vitro protocol. The data also suggests
that photoradiation would be most effective in causing
inhibition of mitochondrial enzymes when employed 24-72h
after administration of the photosensitiser.
Discussion
Clinical treatment of malignancy by photodynamic therapy
(PDT) holds considerable promise but optimisation of
treatment, e.g. selection of sensitiser dose, total light fluence
and timing, and elucidation of the mechanism(s) that result
in retention of these porphyrin species for longer periods in
tumour tissue than most normal tissues, are unresolved.
Although studies of photosensitisation in vitro with any
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sensitiser, including metallophthalocyanines, kryptocyanines,
rhodamines, etc., may provide useful data on selected
parameters, the results may not be readily translatable to
therapy in vivo. Therefore, we examined Photofrin II as we
did previously for HpD (Hilf et al., 1984), utilising an in
vivo-in vitro protocol to investigate the effects of photo-
sensitisation on discrete biochemical parameters. This
protocol allows for metabolism of the sensitiser by the host,
events that may influence equilibration of the sensitiser in
neoplastic cells in vivo. After accounting for appropriate
controls, a demonstration of photosensitisation by in vitro
photoradiation of tumour preparations leads to the
conclusion that a photosensitiser must have been present in
the preparation under study.
The data presented provide the temporal pattern of
Photofrin TI-induced photosensitisation based on its
capability to inhibit selected mitochondrial and cytosolic
enzymes. These results clearly indicate that the greatest
extent of light-induced inhibition of mitochondrial enzyme
activity occurred between 24 and 72h after administration of
Photofrin II in vivo, a result quite comparable to that
observed earlier when HpD was used as the photosensitiser
(Hilf et al., 1984). The results obtained for the cytosolic
enzyme pyruvate kinase, however, were different when
comparing HpD and Photofrin II in this in vivo-in vitro
protocol. Administration of HpD resulted in an early and
dramatic inhibition of pyruvate kinase activity (30min to
24h post-injection) when those tumour cytosols were
exposed to visible light, but after 24h pyruvate kinase
activity was no longer sensitised to light by HpD. However,
the results presented here using Photofrin II show that
pyruvate kinase activity was unaffected throughout the time
course studied. The apparent disparity is probably
attributable to the different compositions of the two
porphyrin preparations. HpD, prepared by the method of
Lipson et al. (1960), is a complex mixture consisting of
numerous hydrophilic and hydrophobic species, estimated
previously to be 75% and 25% of the total porphyrins,
respectively (Hilf et al., 1983). The more hydrophilic
porphyrin species of HpD, such as the isomers of haemato-
porphyrin and hydroxyethylvinyldeuteroporphyrin, were
probably present in sufficient levels in the cytosol soon after
injection such that exposure to light caused oxidative
damage to cytosolic proteins. On the other hand,
Photofrin II, a mixture of porphyrins enriched in the hydro-
phobic species (80-90% as reported by Dougherty (1987)),
presumably dihaematoporphyrin ethers and/or esters
(Berenbaum et al., 1982; Byrne et al., 1987; Dougherty, 1987;
Kessel et al., 1987), would be expected to accumulate
primarily in the more hydrophobic regions, such as cell
membranes. If this were the case, the lower concentration of
hydrophilic components (20%) in Photofrin II would be less
able to produce sufficient 102 in the cytosol to cause
inhibition of pyruvate kinase, the result we observed.
Alternatively, the binding of those hydrophilic components
in Photofrin II may not have been sufficient to maintain a
porphyrin-pyruvate kinase complex for longer periods of
time in vivo, as was suggested by Freitas & Novarina (1987)
for lactate dehydrogenase in HeLa cells. It should be noted
that we administered 80mgkg-1 HpD previously (Hilf et al.,
1984) against 25mg kg-' Photofrin II in the present study
and obtained similar patterns of inhibition of mitochondrial
inner membrane enzymes. A simple calculation shows that
similar amounts of hydrophobic porphyrin components were
administered in both studies, approximately 20mgkg-' from
each preparation.
It is of continued interest that apparent differences exist in
the photosensitivities of mitochondrial enzymes subsequent
to administration of Photofrin II. From studies of enzymes
in vitro, such differences did not appear to be attributable to
intrinsic properties, since inhibitions of semi-purified
enzymes by '02 generation were comparable (Gibson et al.,
1987). Rather, we suggest that such differential sensitivity
probably reflects differences in the immediate environment,
their three-dimensional structure in situ and/or partitioning
of hydrophobic porphyrins. Under the conditions studied
here, the order of photosensitivity was cytochrome c oxidase
>FOF ATPase >succinate dehydrogenase >NADH de-
hydrogenase. Cytochrome c oxidase, however, may possess
some intrinsic properties that render it more sensitive to
damage induced by porphyrin photosensitisation, such as the
presence of hydrophobic regions where porphyrins may
accumulate, since subunits I, II, III and VII display binding
of hydrophobic reagent probes (DeMeis et al., 1988). Also, it
has been proposed that the haems and coppers may be
bound to subunits I and II, although subunits V and VII
have also been implicated as haem binding sites (Azzi, 1980).
Likewise it appears that the active site of mitochondrial F,
ATPase, and of the Ca2+-ATPase of the sarcoplasmic
reticulum, is hydrophobic in nature, since both enzymes were
inhibited by hydrophobic drugs, an effect reversed by the
presence of organic solvents (DeMeis et al., 1988). Taken
together, the greater sensitivities of cytochrome c oxidase
and FOFI ATPase to photosensitisation by Photofrin II may
be attributed to partitioning of the hydrophobic porphyrin
species in or near the active sites of these enzymes. If this
were the case, generation of 102 from illumination could
have significant consequences.
Surprisingly little has been reported regarding the
subcellular distribution of Photofrin II. A number of recent
reports indicate that mitochondrial damage ensues photo-
sensitisation by Photofrin II (Singh et al., 1987; Moreno et
al., 1987), HpD (Berns et al., 1982) and haematoporphyrin
(Salet et al., 1983). The data obtained here demonstrate the
existence of a drug-dose related response of mitochondrial
photosensitisation to Photofrin II. From these data, an
optimum response to illumination should occur at 24-48h
after drug administration, assuming that the biochemical
effects on mitochondria are important for subsequent
cytotoxicity. This does not imply that other events affected
by PDT, such as effects on vascularity (Fingar & Henderson,
1987; Selman et al., 1985; Star et al., 1986), are less
important in producing tumour cell necrosis in the treated
lesions. However the mechanisms for vascular cell damage
might also involve similar cellular sites of action. An
additional consideration is the expected hydrophobic nature
of the inner mitochondrial membrane, which not only should
favour accumulation of hydrophobic components of
Photofrin II, but could also enhance the lifetime of 102
(Parker & Stanbro, 1981), thus increasing the potential
damage.
The data presented here, along with our earlier
observations (Hilf et al., 1984; Murant et al., 1987; Gibson
et al., 1988), allow us to propose a chronology of intra-
cellular distribution of photosensitising components of
Photofrin II in a neoplasm in vivo (Table I). At 2h after
administration of Photofrin II, porphyrins have accumulated
in the plasma membrane and have entered the outer
membrane of mitochondria. This is deduced from the photo-
radiation-induced inhibition of Na+K+ATPase (plasma
membrane) and monoamine oxidase (outer mitochondrial
membrane) at 2h post-treatment. At this early time after
Photofrin II administration, as well as throughout the time-
course studied, neither the cytosolic enzyme pyruvate kinase
nor adenylate kinase, located in the intramembrane space of
mitochondria, were inhibitable by photoradiation in vitro.
Although photoradiation-induced inhibition of the inner
mitochondrial membrane enzymes, succinate dehydrogenase,
cytochrome c oxidase and FOFI ATPase, was seen by 2h
post-treatment, the degree of inhibition of these enzymes
progressively increased to reach a maximum by 24h (Figure
2 and Table I). At the 24h time point, only the inner
mitochondrial membrane enzymes and the plasma membrane
enzyme Na+K+ATPase demonstrated a significant
inhibition. This photosensitisation persisted for 72h, after
which less inhibition resulted from illumination. Thus, if the
effects observed on enzyme activity accurately reflect the
location of photosensitisers, the active components in52 S.L. GIBSON et al.
Table I Photosensitisation of site selected enzymes by Photofrin II
in R3230AC mammary tumours
Time after Photofrin II
administration
Enzyme 2h 24h
Na+K+ATPase 43.8+4.7 55.6+7.0
Mg2+ ATPase 92.2+ 1.8 86.4+2.5
5'-nucleotidase 100+3.4 99.3+3.4
Pyruvate kinase 94.5+3.1 93.8+2.1
Monoamine oxidase 71.8+6.4 86.4+5.5
Adenylate kinase 95.8 + 1.5 93.7+ 1.0
Cytochrome c oxidase 67.0+4.0 26.8+ 1.7
FoF, ATPase 62.6+4.5 34.4+4.2
Succinate dehydrogenase 79.2+2.0 39.7+2.7
NADH dehydrogenase 99.5 +2.2 72.6+ 1.7
Tumour-bearing rats were injected i.p. with 25mgkg-1
Photofrin II, mitochondria prepared from tumours at selected times
and exposed to 300-400Jcm-2 broad band irradiation (see
Materials and methods). Data are presented as percentage of initial
enzyme activity (zero time before photoradiation) +s.e.m. Each
number represents the mean of at least four separate experiments
performed in duplicate. Data for Na+K+ ATPase, Mg2+ ATPase and
5'-nucleotidase are from Gibson et al. (1988) and for monoamine
oxidase and adenylate kinase are from Murant et al. (1987).
Photofrin II demonstrate a time-dependent intracellular
distribution that results in their retention in the plasma
membrane and the inner mitochondrial membrane following
in vivo administration. Bohmer & Morstyn (1985) reported
that cellular uptake of HpD in vitro occurred in two phases;
the first was rapid (seconds) and the porphyrin components
were readily removed by washing with serum-containing
medium, whereas the second phase took hours and the
porphyrins incorporated into the cytosol and intracellular
organelles could not be removed by serum-containing
medium. A somewhat similar pattern was observed by Kessel
(1986) with L1210 cells in vitro by comparing events after
30min, 4 and 18h incubations with HpD. Based on
membrane transport, thymidine incorporation and cellular
ATP levels, the longer incubation times resulted in photo-
sensitised damage at intracellular membrane sites compared
to the plasma membrane damage observed at the shorter
incubation times. Earlier, Moan et al. (1983) observed that,
in NHIK 3025 cells in culture, incubation with HpD for 1
versus 18 h resulted in a change of photosensitisable damage
from the plasma membrane to intracellular sites as
incubation times increased. The differences in the time
course seen in our present study and those of Moan et al. or
Kessel are probably attributable to differences in the
exposure of tumour cells in vivo to circulating levels of
porphyrins, extending the period of time that these cells and
their organelles remain in the presence of the components of
either HpD or Photofrin II.
In conclusion, administration of Photofrin II to tumour-
bearing rats and study of the subsequent photosensitisation
of selected enzymes, i.e. the in vivo-in vitro protocol, results
in mitochondrial enzyme inhibitions that are dependent on
the time interval between administration of the drug and
exposure of the mitochondria to visible light, on the dose of
Photofrin II administered in vivo and on the total fluence
used to photoradiate the samples. Although the data
presented here are in general agreement with data we
previously obtained using HpD as the photosensitiser,
clinical use of Photofrin II will require establishing a
protocol to achieve maximum efficacy.
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